Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam 1
MUMBAI India Sept 21 2021 PRNewswire — Glenmark Pharmaceuticals Ltd Glenmark has received final approval by the United States Food Drug Administration US FDA for Clindamycin Phosphate Foam 1 the generic version of Evoclin1 Foam 1 of Mylan Pharmaceuticals Inc According to IQVIATM sales data for the 12 month period ending July 2021 the Evoclin Foam 1 market2 achieved annual sales of approximately 120 million Glenmarks current portfolio consists of 173 products authorized for distribution in the US marketplace and 47 ANDAs pending approval with the US FDA In addition to these internal filings Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio References 1All brand names and trademarks are the property of their respective owners 2Market includes brand and all available therapeutic equivalents IQVIATM National Sales Perspectives Retail Non-Retail July 2021 About Glenmark Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd GPL is a global research-led pharmaceutical company with presence across Generics Specialty and OTC business with operations in over 50 countries Glenmarks key therapy focus areas globally are respiratory dermatology and oncology It ranks among the worlds top 50 Generics and Biosimilars companies Top 50 Company Rankings 2020 from Informas Generics Bulletin The company has been listed in the Dow Jones Sustainability Index DJSI under the category of emerging markets for the third consecutive year in a row DJSI is one of the worlds most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index For more information visit wwwglenmarkpharmacom Logo httpmmaprnewswirecommedia451507PRNEGlenmarkLogojpg PWR PWR
MUMBAI India Sept 21 2021 PRNewswire — Glenmark Pharmaceuticals Ltd Glenmark has received final approval by the United States Food Drug Administration US FDA for Clindamycin Phosphate Foam 1 the generic version of Evoclin1 Foam 1 of Mylan Pharmaceuticals Inc According to IQVIATM sales data for the 12 month period ending July 2021 the Evoclin Foam 1 market2 achieved annual sales of approximately 120 million Glenmarks current portfolio consists of 173 products authorized for distribution in the US marketplace and 47 ANDAs pending approval with the US FDA In addition to these internal filings Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio References 1All brand names and trademarks are the property of their respective owners 2Market includes brand and all available therapeutic equivalents IQVIATM National Sales Perspectives Retail Non-Retail July 2021 About Glenmark Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd GPL is a global research-led pharmaceutical company with presence across Generics Specialty and OTC business with operations in over 50 countries Glenmarks key therapy focus areas globally are respiratory dermatology and oncology It ranks among the worlds top 50 Generics and Biosimilars companies Top 50 Company Rankings 2020 from Informas Generics Bulletin The company has been listed in the Dow Jones Sustainability Index DJSI under the category of emerging markets for the third consecutive year in a row DJSI is one of the worlds most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index For more information visit wwwglenmarkpharmacom Logo httpmmaprnewswirecommedia451507PRNEGlenmarkLogojpg PWR PWR
